Y-NM600 for Metastatic Cancer with Anti-PD-1 or Anti-PD-L1 Therapy
This study is testing a new treatment called Y-NM600 for people with metastatic cancer (cancer that has spread) who are already receiving anti-PD-1 or anti-PD-L1 therapy. The main goal is to find the safest and most effective dose of 90Y-NM600 and to see if it can improve how well current drug therapies work. Researchers will also use an imaging agent, 86Y-NM600, to help decide who can receive 90Y-NM600. Up to 60 participants will join, and you could be in the study for up to 9 months. The study is looking for people with squamous cell carcinoma (a type of skin cancer) that started in the head and neck region.
- Study design
- This is an interventional study that will enroll up to 60 participants. It includes a dose-finding phase to determine the optimal dose of 90Y-NM600.
- What's involved
- You would receive injections of 86Y-NM600 and 90Y-NM600, and undergo PET/CT imaging. You could be on the study for up to 9 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for toxicities (side effects) up to 9 months after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Grace Blitzer, MD · PRINCIPAL_INVESTIGATOR · UW Carbone Cancer Center
- Justine Bruce, MD · PRINCIPAL_INVESTIGATOR · UW Carbone Cancer Center
- Zachary Morris, PhD · STUDY_CHAIR · UW Carbone Cancer Center
- Paul Harari, MD · STUDY_CHAIR · UW Carbone Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600baseline screening, Day 7 after 86Y-NM600 injection
Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600 by day 7 (greater than 10 half-lives of 86Y) after 86Y-NM600 injection, as defined by the NCI CTCAE version 5.0.
- Toxicities greater than or equal to Grade 3 at least possibly related to 90Y-NM600up to 9 months on study
Toxicities greater than or equal to Grade 3 at least possibly related to 90Y-NM600 by day 42 after final 90Y-NM600 injection, as defined by the NCI CTCAE version 5.0. Time points of investigation include: * baseline screening * Phase 1A: post injection week 1, week 2, week 3, week 4 * Phase 1B: 7 days after each injection, 30 days and 42 days after final injection